Grifols to sell assets to clear way for Talecris takeover
Grifols is to sell a facility as part of a US FTC consent agreement that, if approved, will allow it to buy Talecris Biotherapeutics.
In a consent agreement signed with US Federal Trade Commission (FTC) staff Grifols said it will sell a Melville, New York fractionation facility to Italy-based Kedrion. If FTC Commissioners approve the agreement Grifols will be cleared to complete the $4bn (€2.7bn) takeover of Talecris.
Completion of the deal would help Grifols compete against Baxter and CSL, its rivals in the US blood-based infusions market. CSL previously attempted to buy Talecris but the FTC objected.
To appease the FTC Grifols has agreed to sell three units to Kedrion: the Melville facility, which Grifols will manage for up to four years under a lease agreement; Talecris’ FVIII US business; and two plasma collection centres.
